CytomX Therapeutics (NASDAQ:CTMX) Announces Quarterly Earnings Results

Share on StockTwits

CytomX Therapeutics (NASDAQ:CTMX) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.13), Fidelity Earnings reports. CytomX Therapeutics had a negative net margin of 158.05% and a negative return on equity of 77.05%. The firm had revenue of $10.71 million during the quarter, compared to the consensus estimate of $23.58 million.

Shares of NASDAQ CTMX traded down $0.20 during mid-day trading on Friday, reaching $5.95. 538,700 shares of the company were exchanged, compared to its average volume of 437,329. The company’s 50 day moving average price is $7.14 and its 200 day moving average price is $9.47. CytomX Therapeutics has a 52 week low of $5.28 and a 52 week high of $19.75. The stock has a market capitalization of $281.99 million, a PE ratio of -2.93 and a beta of 0.64. The company has a quick ratio of 4.66, a current ratio of 4.66 and a debt-to-equity ratio of 0.26.

Several research analysts have commented on CTMX shares. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. BidaskClub downgraded shares of CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 1st. Nomura reissued a “buy” rating and issued a $22.00 price target on shares of CytomX Therapeutics in a report on Sunday, August 11th. Cowen reissued a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, August 7th. Finally, Mizuho reissued a “buy” rating and issued a $16.00 price target on shares of CytomX Therapeutics in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $20.14.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Further Reading: Why is Cost of Capital Important?

Earnings History for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

PotNetwork  Stock Price Down 0.3%
PotNetwork Stock Price Down 0.3%
MUFG Americas Holdings Corp Has $19.61 Million Stake in AT&T Inc.
MUFG Americas Holdings Corp Has $19.61 Million Stake in AT&T Inc.
MUFG Americas Holdings Corp Trims Stock Position in Analog Devices, Inc.
MUFG Americas Holdings Corp Trims Stock Position in Analog Devices, Inc.
MUFG Americas Holdings Corp Grows Stock Holdings in iShares Gold Trust
MUFG Americas Holdings Corp Grows Stock Holdings in iShares Gold Trust
Tower Research Capital LLC TRC Sells 1,523 Shares of Goldman Sachs Group Inc
Tower Research Capital LLC TRC Sells 1,523 Shares of Goldman Sachs Group Inc
PFSweb  Releases Quarterly  Earnings Results, Beats Estimates By $0.13 EPS
PFSweb Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS


 
© 2006-2019 Zolmax.